Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure.

Abstract

Unlike other antiarrhythmic class I drugs, amiodarone showed in preliminary studies, benefits also in patients with left ventricular dysfunction. These positive results have induced the development of large randomised controlled studies: their results are reviewed and the controversial points are discussed. In a meta-analysis of randomised controlled trials the use of amiodarone in heart failure was associated with an approximate 20 to 25% reduction in deaths. However, amiodarone was also associated with a 120 to 124% increase in side effects.

• Authors: M Piepoli, G Q Villani, P Ponikowski, A Wright, M D Flather, A J Coats
• Journal: International journal of cardiology (Int J Cardiol) Vol. 66 Issue 1 Pg. 1-10 (Sep 01 1998) ISSN: 0167-5273 [Print] Netherlands
• PMID: 9781781 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Anti-Arrhythmia Agents
• Amiodarone

Topics

• Amiodarone (adverse effects, therapeutic use)
• Anti-Arrhythmia Agents (adverse effects, therapeutic use)
• Chronic Disease
• Heart Failure (drug therapy, mortality)
• Humans
• Odds Ratio
• Randomized Controlled Trials as Topic
• Survival Analysis